Sanofi forms drug dis­cov­ery pact with French start­up Aqemia en route to ‘AI at scale’ am­bi­tion

Sanofi CEO Paul Hud­son has been clear about his com­pa­ny’s bets on drug dis­cov­ery’s hottest tech­nol­o­gy — tout­ing plans to be the “first phar­ma com­pa­ny pow­ered by ar­ti­fi­cial in­tel­li­gence at scale” — and it has now lined up an­oth­er pact to get there.

The French phar­ma gi­ant will pay up to $140 mil­lion to Paris-based Aqemia as part of a mul­ti-year col­lab­o­ra­tion to cre­ate small mol­e­cules for more than one ther­a­peu­tic area. Fur­ther de­tails on the up­front break­down, time­line and spe­cif­ic dis­ease ar­eas were kept un­der wraps.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER